Germany Amyotrophic Lateral Sclerosis (ALS) Market Insight
Published: 04 June 2026 | Report Format: Electronic (PDF)
The market for amyotrophic lateral sclerosis (ALS) in Germany is expected to develop at a pace of 7.16% as a result of growing neurological therapy uptake, better medicines, and an increase in cases.
Germany Amyotrophic Lateral Sclerosis (ALS) Market Insights Forecasts to 2035
- The Germany Amyotrophic Lateral Sclerosis (ALS) Market Size Was Estimated USD 150.3 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.16% from 2025 to 2035
- The Germany Amyotrophic Lateral Sclerosis (ALS) Market Size is Expected to rise around USD 300.1 Million by 2035
Notable Insights for the Germany Amyotrophic Lateral Sclerosis (ALS) Market
- Based on treatment type segmentation, German market for amyotrophic lateral sclerosis (ALS) will be dominated by medications, with the largest proportion coming from symptomatic treatments, disease-modifying medications, and clinical adoption.
- Based on drug class segmentation, shows that glutamate inhibitors are the most common in Germany. Riluzole will lead the market for amyotrophic lateral sclerosis (ALS) in 2025, followed by antioxidants and the quickly expanding gene and ASO treatments.
- Germany's ALS market epidemiology and demand estimates are supported by population-based data from the swabia registry in southern Germany, which reveals a crude ALS incidence rate of 2.6 cases per 100,000 person-years.
- With businesses like qurAlis raising roughly $88 million for the development of QRL-201 and QRL-101, which target motor neuron degeneration across worldwide neurodegenerative therapeutic pipelines, funding for ALS precision medicines is growing.
Download the eBook (ToC)
Why Buy This Report
- enables precise revenue planning and long-term strategic decision-making for ALS medication and therapy stakeholders by providing comprehensive market estimates and predictions from 2025 to 2035.
- provides accurate demand estimation for ALS medicines and supportive care solutions by analyzing epidemiology specific to Germany, including incidence, prevalence, and patient pool trends.
- helps businesses find high-growth areas and efficiently select investment possibilities by providing thorough segmentation by drug class, treatment type, and care setting.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Germany amyotrophic lateral sclerosis (ALS) market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Germany Amyotrophic Lateral Sclerosis (ALS) Market
- Sanofi
- Biogen
- Mitsubishi Tanabe Pharma
- Novartis
- Merck KGaA
- Alexion Pharmaceuticals (AstraZeneca)
- F. Hoffmann-La Roche
- Teva Pharmaceutical Industries
- Orion Corporation,
- Apotex
Recent Developments:
- In April 2025, expanded European approval for Radicava increased its availability in Germany and facilitated patients' access to disease-modifying treatments.
- In March 2025, clinical trial skills and speed up the development of precision medicine, Biogen worked with German ALS clinics and European research institutes to advance genetic-targeted medicines.
Market Segmentation:
Germany Amyotrophic Lateral Sclerosis (ALS) Market, By Treatment Type
- Medications
- Therapies
- Devices & Respiratory Support
Germany Amyotrophic Lateral Sclerosis (ALS) Market, By Drug Class
- Glutamate Inhibitors
- Antioxidants / Free Radical Scavengers
- Gene & Antisense Oligonucleotide (ASO) Therapies
Germany Amyotrophic Lateral Sclerosis (ALS) Market, By Route of Administration
- Oral
- Intravenous (IV)
- Intrathecal
Expert Views:
Growth of the Germany amyotrophic lateral sclerosis (ALS) market is evident from rising incidences of ALS cases, increasing adoption of disease modifying therapies, and expansion in pipelines for precision medicines. Growth prospects for Germany’s dominance in the European ALS market till 2035 are ensured through further innovations in regulation, clinical partnerships, and gene therapies.
Author: Govind and Krishna By Spherical Insights and Consulting